Neeman medical International is presently enrolling neonates or infants with cyanotic congenital heart disease palliated with a systemic to pulmonary artery shunt. The study is a phase III study wit global enrollment of 490 subjects across 31 countries.

For more details on the study, please visit:

http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00396877?order=1